newsfilter
← Latest News
GlobeNewswire·

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025Phase 2 trial of RAP-219 in bipolar mania has been initiated and is